RPG Life Sciences Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹4,402 Cr
- Book Value
- ₹366.10
- Stock P/E
- 37.70
- Dividend Yield
- 0.87%
- ROE
- 19.31%
- ROCE
- 25.71%
- PEG Ratio
- 1.74
- EV/EBITDA
- 24.48
Fundamentals from Screener.in, as of 6 Aug 2026. Live price via Yahoo Finance.
RPG Life Sciences share price today
RPG Life Sciences (NSE: RPGLIFE) was priced at ₹2,661.30 in Gale’s internal stock-universe snapshot dated 6 August 2026. Applied to the 16,539,015 issued shares in the FY26 annual report, that price implies a market capitalisation of approximately ₹4,402 crore. Its recorded 52-week range was ₹1,744 to ₹3,017.10, leaving the share about 11.8% below the high. The quote widget can move with the market; the ratios and valuation model below remain fixed to that research date.
The company has become a focused domestic-formulations compounder with smaller international-formulations and active-pharmaceutical-ingredient businesses. The quality case is credible: return on capital employed was 25.71% in Gale’s snapshot, promoter pledge was recorded as nil, and Q1 FY27 delivered revenue and profit growth together. The harder part is valuation. A high-thirties earnings multiple leaves little room for a relapse in margin, a slow international pipeline or another manufacturing interruption.
What RPG Life Sciences actually does
RPG Life Sciences develops, manufactures and markets branded medicines in India and Nepal, oral solid generics and branded generics overseas, and selected synthetic APIs. The FY26 annual report describes export relationships across more than 60 countries and leadership in immunosuppressants. Its product catalogue spans nephrology, rheumatology, oncology, pain management, cardio-metabolic care, urology, neuropsychiatry and gastroenterology.
| FY26 business | Share of sales | Commercial character |
|---|---|---|
| Domestic formulations | 68.9% | Branded prescriptions, doctor coverage and lifecycle management |
| International formulations | 17.6% | Registrations, partner relationships and regulated-market compliance |
| APIs | 13.5% | Niche, lower-volume molecules plus backward integration |
This mix is important. Domestic brands provide the repeat-prescription economics that support group profitability. International formulations and APIs add optionality, but they also introduce registration lead times, customer concentration, plant-utilisation and compliance risk. The company should therefore be assessed as three linked engines, not as a generic “pharma growth” story.
Q1 FY27 put growth and margin back together
The official 28 July presentation, released before Gale’s snapshot, showed a strong June quarter. Consolidated revenue increased 15.8%, EBITDA grew 17.9%, and profit after tax excluding exceptional items rose 17%. Margins improved slightly rather than being sacrificed for the higher sales line.
| Consolidated result | Q1 FY26 | Q1 FY27 | Change |
|---|---|---|---|
| Revenue from operations | ₹168.9 Cr | ₹195.7 Cr | +15.8% |
| EBITDA | ₹40.7 Cr | ₹48.0 Cr | +17.9% |
| EBITDA margin | 24.1% | 24.5% | +40 bps |
| PBT | ₹35.4 Cr | ₹41.5 Cr | +17.0% |
| PAT, excluding exceptional items | ₹26.3 Cr | ₹30.8 Cr | +17.0% |
| PAT margin | 15.6% | 15.7% | Broadly stable |
One good quarter is not a complete trend, but this was higher-quality growth than revenue alone would suggest. Domestic formulations continued to lead, international sales moved forward, and API revenue recovered faster from a depressed base. The next test is whether the company can repeat that combination after launch spending and manufacturing investment rise.
FY26 needs to be read through the exceptional items
FY26 revenue rose 8.3% to ₹707.5 crore, but normalised profitability did not keep pace. Company-reported EBITDA was virtually unchanged and its margin contracted by two percentage points. PBT and PAT excluding exceptional items were also almost flat.
| Company-adjusted FY26 measure | FY25 | FY26 | Reading |
|---|---|---|---|
| Revenue | ₹653.4 Cr | ₹707.5 Cr | +8.3% |
| EBITDA | ₹172.3 Cr | ₹172.7 Cr | Nearly flat |
| EBITDA margin | 26.4% | 24.4% | Lower by 200 bps |
| PBT excluding exceptional items | ₹150.3 Cr | ₹150.3 Cr | Flat |
| PAT excluding exceptional items | ₹111.6 Cr | ₹111.7 Cr | Flat |
| Adjusted PAT margin | 17.1% | 15.8% | Lower mix and operating absorption |
Reported net profit is especially easy to misread. FY25 included a large profit from assigning surplus leasehold land. FY26 exceptional items combined fire-insurance income with costs for new labour codes and an intangible-asset write-off. The annual report puts the net FY26 exceptional gain at ₹3.90 crore versus ₹82.60 crore in FY25. Comparing reported EPS across those years without normalisation would understate the operating stability and overstate the underlying decline.
Domestic formulations remain the economic engine
Domestic formulations generated ₹483.5 crore in FY26, up 13.7%, while the company cited Indian pharmaceutical market growth of 8.6%. Q1 FY27 extended that lead: domestic segment sales increased 14.8% to ₹132.5 crore and represented 68.3% of the quarter’s sales.
The advantage is not simply having more products. RPG Life Sciences concentrates on established “textbook” brands such as Azoran, Aldactone, Lomotil, Naprosyn, Serenace and Norpace, then extends their relevance through new indications, formulations and specialist reach. Prescription familiarity can make revenue durable, but every brand still competes for doctor attention and must remain clinically and commercially relevant.
| Domestic growth lever | Evidence | What must continue |
|---|---|---|
| Core brands | Naprosyn grew 15.6% in FY26 | Brand growth without excessive promotion |
| Specialty therapies | Nephrology, rheumatology and oncology grew strongly | Repeat prescriptions and accepted launches |
| Field productivity | Overall monthly productivity reached ₹6.5 lakh per representative | Coverage quality, not only headcount |
| New products | Chronic, biosimilar and specialty portfolio expanded | Meaningful sales after launch spending |
| Lifecycle management | Line extensions and new patient segments | Protection of brand equity and pricing |
Immunosuppressants create a specialist franchise
Immunosuppressants connect all three operating arms. Domestic nephrology brands build specialist relationships, international formulations sell products such as azathioprine, and the API operation provides selected backward integration. This overlap can improve technical knowledge, supply reliability and customer trust.
Management has outlined an ambition to build the immunosuppressant portfolio beyond ₹200 crore. That is a direction, not contracted revenue. These medicines require reliable quality systems and careful medical engagement, while competitors can enter with approved alternatives. The evidence that matters is sustained specialist prescription growth, successful registrations and an acceptable return on the capacity used to serve them.
Digital tools can improve field economics
The annual report says RPGServ supports engagement with more than 100,000 doctors, including over 36,000 specialists. The company is adding AI-led segmentation and personalised engagement, while its manufacturing and quality functions use digital monitoring and electronic documentation.
Digital reach is useful when it makes the sales force more productive or improves compliance. It is not valuable merely because a platform has many enrolled doctors. Investors should look for higher sales per representative, lower execution errors and better launch conversion. FY26’s rise in overall productivity from ₹5.7 lakh to ₹6.5 lakh per representative per month is a tangible output; platform registrations are an input.
International formulations are the slower second engine
International formulations declined 6.7% in FY26 to ₹123.4 crore before returning to 7.7% growth in Q1 FY27. The portfolio includes oral solids and immunosuppressants sold through partners across regulated and emerging markets. Products made under low-humidity or low-temperature conditions can face less competition than ordinary tablets, but approvals and customer onboarding take time.
| International opportunity | Potential advantage | Principal risk |
|---|---|---|
| Regulated markets | Higher qualification and compliance barriers | Audit observations or delayed registrations |
| Emerging markets | More geographies and branded-generic demand | Currency, political and collection risk |
| Immunosuppressants | Existing molecule and manufacturing knowledge | Product or partner concentration |
| New customers | Better utilisation of approved facilities | Price negotiation and long validation cycles |
A credible turnaround would show growth across more than one customer or geography. Quarterly revenue can be lumpy when orders wait for registration, tender or shipment. The segment should earn its valuation through repeat supply and cash generation, not a large addressable-market estimate.
API recovery is real but still needs proof
An incident at the Navi Mumbai API facility disrupted FY26 output. The annual report says the affected unit was restored, validations completed and the plant returned to full operation. API revenue still grew 5.3% for FY26 and then rose 35.6% year on year to ₹26.6 crore in Q1 FY27.
The rebound is encouraging because the API business supplies high-value, lower-volume molecules and supports formulation security. It should not be annualised mechanically: the comparison includes a disrupted base, and post-restoration customer qualification can produce uneven shipments. The next evidence is stable production, no quality event, a broader customer book and margins that justify the specialist plant.
Manufacturing quality is part of the moat
RPG Life Sciences operates formulation facilities at Ankleshwar and an API site in Navi Mumbai. Its disclosed approvals include EU GMP, Australia’s TGA and Japan’s PMDA, while different units serve domestic, emerging and regulated markets. Such approvals allow participation; they do not guarantee orders.
The company says more than ₹185 crore has been invested in capacity and plant modernisation since FY22. R&D expenditure also rose from ₹7.23 crore in FY25 to ₹9.84 crore in FY26, principally for formulation projects. These investments are constructive if they produce launches, registrations, better yields and higher utilisation. Otherwise, depreciation and fixed overhead can outrun revenue.
| Capability investment | Intended output | Investor checkpoint |
|---|---|---|
| Plant modernisation | More capacity and audit readiness | Utilisation and clean inspections |
| Formulation R&D | Specialty and chronic launches | Approval rate and post-launch sales |
| Digital quality systems | Traceability and fewer deviations | Regulatory record and batch reliability |
| API restoration | Recovered niche-molecule supply | Customer revalidation and unit margin |
Cash flow was weaker than accounting profit
Consolidated operating cash flow declined to about ₹56.5 crore in FY26 from ₹77.9 crore. At the same time, capital spending on property, plant, work in progress and intangibles was about ₹65.4 crore, leaving free cash flow slightly negative before other investing movements. The company nevertheless reported roughly ₹275 crore of cash reserves, so one investment-heavy year is manageable.
Working capital explains part of the gap. Screener records debtor days rising from 48 to 60, inventory days from 159 to 179 and the cash-conversion cycle from 72 to 99 days. Official year-end inventory increased from ₹92.98 crore to ₹123.84 crore. Some build may support recovery and launches, but it must convert to sales and collections.
| Cash discipline measure | FY25 | FY26 | Direction |
|---|---|---|---|
| Operating cash flow | ₹77.9 Cr | ₹56.5 Cr | Weaker |
| Inventory | ₹92.98 Cr | ₹123.84 Cr | More cash tied up |
| Debtor days | 48 | 60 | Collections lengthened |
| Cash-conversion cycle | 72 days | 99 days | Funding need increased |
| Approximate cash reserves | — | ₹275 Cr | Strong liquidity buffer |
The balance sheet supports measured investment
Year-end borrowings were ₹20 crore, relating to a secured capex facility carrying 7.85% interest and repayable in quarterly instalments. That is modest beside cash reserves, and the June 2026 credit update reaffirmed the company’s A+ long-term rating with a stable outlook and A1 short-term rating.
The balance sheet creates options for internal investment or a targeted acquisition. It does not make every acquisition sensible. Management has described a framework covering therapies, brands and strategic fit. Any transaction should be judged on integration cost, durable cash earnings and return on incremental capital rather than the immediate revenue added.
Gale’s 6 August valuation snapshot
| Snapshot metric | Recorded value |
|---|---|
| Share price | ₹2,661.30 |
| Market capitalisation | ₹4,402 Cr |
| P/E, normalised to snapshot price | 37.70× |
| Price to book, normalised to snapshot price | 7.27× |
| EV/EBITDA | 24.48× |
| PEG ratio | 1.74 |
| EPS, TTM | ₹70.60 |
| Book value per share | ₹366.10 |
| ROE | 19.31% |
| ROCE / five-year ROCE | 25.71% / 31.47% |
| Operating margin | 21.14% |
| Dividend yield | 0.87% |
| Promoter pledge | Nil |
The source row’s stored market capitalisation, P/E and price-to-book columns were captured against an earlier quote near ₹2,745, while its 6 August price column was ₹2,661.30. To avoid displaying ratios from two price timestamps as if they were simultaneous, the table above recomputes market capitalisation from official issued shares, P/E from the recorded ₹70.60 EPS and price to book from the ₹366.10 book value. The target model still uses the same EPS input. EV/EBITDA is retained as the source ratio because it also depends on enterprise-value and EBITDA refreshes.
The return profile is strong for a company of this size, but the valuation already assumes continued branded-formulation compounding. Price to book is especially demanding when ROE is below the five-year ROCE history, while EV/EBITDA leaves limited protection against margin normalisation. Q1 supports the growth case; it does not eliminate entry-price risk.
How the valuation scenarios are built
The model starts with the internal TTM EPS of ₹70.60. Each scenario compounds that base at a distinct annual rate and applies a terminal P/E. Since the research date is 6 August, the 2026 horizon contains only 147/365 of a year; later rows add one full year at a time. Every result is rounded to the nearest ₹5.
| Scenario | EPS growth | Exit P/E | Operating interpretation |
|---|---|---|---|
| Bear | 8% | 26× | Domestic growth slows and the premium multiple compresses |
| Base | 13% | 34× | Brands compound while API and overseas execution improve |
| Bull | 18% | 42× | Specialty launches scale with sustained margin and cash returns |
The model deliberately separates business progress from the multiple investors may pay. A good quarter can lift EPS without preventing a de-rating. Conversely, steady compounding can create value after an overly optimistic multiple has normalised. The assumptions are sensitivities, not company guidance.
RPG Life Sciences share price target 2026 to 2030
The member table contains the annual bear, base and bull calculations. The base path requires domestic formulations to retain market-beating growth, international products to regain momentum and API recovery to remain compliant. The bull path additionally needs successful specialty launches and strong cash conversion. The bear path captures the risk that good operating results are offset by multiple compression.
What would strengthen or weaken the thesis
| Evidence to monitor | Constructive signal | Adverse signal |
|---|---|---|
| Domestic formulations | Growth remains ahead of the market | Field expansion fails to lift productivity |
| Core and new brands | Repeat growth after launch periods | Promotion rises without prescription traction |
| International business | Registrations become diversified repeat sales | One customer or market drives volatility |
| API plant | Stable output and profitable customer return | Another disruption or delayed qualification |
| Cash conversion | CFO follows adjusted profit | Inventory and receivables keep rising faster |
| Capital allocation | ROCE remains healthy after capex or M&A | Cash reserve is spent without incremental returns |
Risks investors should keep separate
- Regulatory and quality risk: an adverse inspection, data-integrity issue or product recall can interrupt supply and damage approvals.
- Brand risk: textbook brands are durable, but doctor preference, price controls and competing launches can slow them.
- Manufacturing risk: the API fire demonstrated that one block can affect a full year’s segment growth.
- Pipeline risk: formulation R&D and registrations may consume cash without producing commercial sales on schedule.
- Working-capital risk: long inventory and collection cycles can make profit growth less cash generative.
- Acquisition risk: a new brand or company may be strategically adjacent yet financially expensive.
- Valuation risk: a premium multiple can fall even when the underlying business remains healthy.
Should you buy RPG Life Sciences at the current price?
RPG Life Sciences has a focused domestic franchise, specialist immunosuppressant knowledge, recovering API operations and a liquid balance sheet. Q1 FY27 provided welcome evidence that growth can return without sacrificing margin. The valuation, however, requires several years of clean execution. Existing investors can monitor adjusted profit, cash flow and return on new capital. Prospective investors should use the gated panel to impose price discipline rather than treating branded-pharma quality as an unlimited valuation argument.
FAQ
What is the RPG Life Sciences share price target for 2030?
Gale’s member table shows annual bear, base and bull scenarios calculated from TTM EPS, explicit growth assumptions and terminal P/E multiples. They are valuation sensitivities, not guaranteed future prices.
Why did reported FY26 profit fall despite revenue growth?
FY25 included a large land-assignment gain, while both years contained different exceptional items. On the company’s adjusted basis, FY26 PAT was broadly flat, making normalised profit and cash flow more useful than the reported year-on-year comparison.
What is RPG Life Sciences’ largest business?
Domestic formulations are the core, contributing about 69% of FY26 sales. International formulations contributed about 18% and APIs the remaining 13%.
Has the API plant recovered from the fire?
The company says the affected unit was restored and the plant became fully operational. Q1 FY27 API growth supports recovery, but several quarters of stable production and cash contribution are better evidence than one base-effect comparison.
Why does working capital matter for this company?
Inventories and receivables rose in FY26, causing operating cash flow to trail accounting profit. Continued growth is higher quality if these balances convert into collections rather than remaining permanently elevated.
When are RPG Life Sciences’ next results?
Use Gale’s results calendar and confirm the final date in the company’s exchange announcement before acting.
Related pharmaceutical research
- Mankind Pharma share price target 2030
- Torrent Pharma share price target 2030
- Zydus Lifesciences share price target 2030
- Natco Pharma share price target 2030
Sources and methodology
- RPG Life Sciences Q1 FY27 investor presentation
- RPG Life Sciences FY26 annual report
- RPG Life Sciences Q4 and FY26 presentation
- RPG Life Sciences investor-relations presentation archive
- RPG Life Sciences on Screener
This article is independent research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. Drug approvals, prescriptions, plant operations, financial results and market prices can change quickly. Verify current company filings, diversify appropriately and consult a SEBI-registered adviser where necessary.